Cencora

(New York Stock Exchange)
Back to all articles
Bullish +65

Cencora to Acquire American Oncology Network to Strengthen Support of ...

Acquisition AI-generated analysis

πŸ“ˆ Cencora signed a definitive agreement to acquire American Oncology Network (AON), a physician-led network of over 350 oncology providers across 21 states.

πŸ’° The transaction values AON at an enterprise value of $2.4 billion, consisting of $2.3 billion at closing and up to $100 million in contingent value rights (CVRs).

🀝 Cencora currently holds approximately 4% of AON equity and plans to acquire the remaining interests, potentially increasing its stake to 75% via an equity rollover.

πŸ“‰ Financial guidance update: Cencora raised adjusted diluted EPS expectations for fiscal year 2026 to at least $17.90, reflecting strength in its U.S. Healthcare Solutions segment.

πŸš€ Strategic impact: The acquisition is expected to be accretive to Cencora's adjusted diluted EPS in the second year post-closing.

🌍 Expansion scope: The deal expands Cencora's MSO platform and presence across twelve additional states, strengthening its support for independent oncology practices.

βš–οΈ Regulatory status: The transaction is subject to customary closing conditions, including receipt of required regulatory clearances and AON stockholder approvals.

πŸ‘₯ Leadership alignment: Todd Schonherz, CEO of AON, noted that Cencora understands the mission of high-quality, accessible cancer care delivered close to home.

πŸ“… Forward-looking outlook: Cencora will discuss expectations for fiscal 2027 on its fourth quarter earnings call scheduled for November 4, 2026.

Bullish Signals
  • Cencora announced a definitive agreement to acquire American Oncology Network (AON), expanding its physician-led oncology MSO platform and strengthening patient access to high-quality care.
  • The acquisition of AON is expected to be accretive to Cencora's adjusted diluted EPS in the second year post-closing, indicating immediate financial value creation.
  • Cencora updated its fiscal year 2026 guidance to raise adjusted diluted EPS expectations to at least $17.90, reflecting strong performance in its U.S. Healthcare Solutions segment.
  • The deal values AON at an enterprise value of $2.4 billion, with Cencora acquiring the remaining equity interests to increase its ownership stake to 75%.
Risk Factors
  • The transaction is subject to customary closing conditions, including receipt of required regulatory clearances and AON stockholder approvals, which could delay or prevent completion.
Full Analysis
Cencora, Inc. (NYSE: COR) announced a definitive agreement to acquire American Oncology Network (AON), a physician-led network comprising over 350 oncology providers across 21 states. The deal aims to expand Cencora's Managed Services Organization (MSO) platform and strengthen its presence in twelve additional states, thereby enhancing support for independent oncology practices. The transaction values AON at an enterprise value of $2.4 billion, with Cencora acquiring the remaining equity interests it does not currently hold. Assuming certain stockholders participate in an equity rollover, Cencora expects to pay approximately $1.7 billion at closing to increase its ownership stake to 75%, with up to $100 million in contingent value rights (CVRs) payable upon meeting specific conditions. Cencora updated its fiscal year 2026 financial guidance to reflect the strength of its U.S. Healthcare Solutions segment, raising adjusted diluted EPS expectations to at least $17.90. Management expects the acquisition to be accretive to adjusted diluted earnings per share in the second year post-closing, signaling confidence in the strategic value of integrating AON's physician-led model. The acquisition is subject to customary closing conditions, including regulatory clearances and stockholder approvals. Cencora plans to discuss its expectations for fiscal 2027 on its upcoming fourth quarter earnings call, maintaining confidence in continued growth within its Healthcare Solutions segments.